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Abstract
Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in
pediatric patients. Here, we investigated differences between age- and gender-normed bodymass index–standardized z scores
at baseline and after 8 weeks of open-label, flexible-dose risperidone treatment (mean dose: 1.70mg/day) in 32 youths with
pervasive developmental disorder (mean age¼ 8.74, range¼ 5–16 years) in relation to 759C/T 5-hydroxytryptamine 2C
receptor (HTR2C) promoter and rs1414334 HTR2C intragenic C/G alleles, along with gender, age, and risperidone dose,
using repeated measures analyses of variance. Carriers of the HTR2C promoter T allele gained an average of 0.043 0.017
body mass index–standardized z scores (1.84 1.51 kg) versus 0.64 0.35 z (3.23 1.47 kg) for non–T-allele carriers
( p< 0.001). Presence of the rs1414334C allele played no significant role. Further, weight gain appeared to be associatedwith
younger age and higher doses of risperidone. The current preliminary findings suggest that the variant T allele of the759C/T
HTR2C promoter polymorphism is protective against risperidone-induced weight gain. Younger children and those treated
with higher doses of risperidone may be at higher risk for weight gain.
Introduction
The efficacy of the antipsychotic agent risperidone inameliorating disruptive and aggressive behavior is well es-
tablished for children and adolescents with pervasive develop-
mental disorder (Research Units on Pediatric Psychopharmacology
Autism Network 2002; Troost et al. 2005) or intellectual disability
(Findling et al. 2004). However, weight gain is an important
adverse effect of risperidone, particularly for children (Safer 2004),
mean gains being in the range of 2.2–2.8 kg in the first 8 weeks of
treatment in controlled studies (Findling et al. 2004; Shea et al.
2004; Troost et al. 2005; Fleischhaker et al. 2007). Weight gain has
well-established health risks, which may include glucose dysre-
gulation, future cardiovascular disease, and development of the
metabolic syndrome (Chia and Boston 2006); it may also have
psychosocial consequences resulting from lowered self-esteem and
social isolation (Puhl and Latner, 2007).
Although a pooled data analysis of available studies until mid-
2003 suggested that younger children may be at a higher risk for
weight gain when treated with risperidone (Safer 2004), determi-
nants that increase or decrease the risk of risperidone-induced
weight gain in pediatric patients have not been clearly established.
For example, risperidone dose, concomitant medication use, age,
pubertal status, gender, and baseline weight and body mass index
(BMI) have not been predictive of weight gain in controlled studies
(Hellings et al. 2001; Aman et al. 2005) and a retrospective chart
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review (Martin et al. 2004). A recent study, however, suggested
that baseline BMI was negatively correlated with weight gain
through long-term use of risperidone (Calarge et al. 2009). Thus far,
the possible contribution of genetic factors to the susceptibility of
weight gain in children treated with risperidone has not been
evaluated.
Studies with adult patients have found evidence that genetic
variation in the gene coding for the 5-hydroxytryptamine 2C
(5HT2C) receptor (HTR2C gene; located on the X chromosome at
q24) is associated with interindividual differences in antipsychotic-
induced weight gain (Reynolds et al. 2002). More precisely, pres-
ence of the variant T allele of the 759C/T polymorphism in the
promoter region of the HTR2C gene (rs3813929) has been dem-
onstrated to have protective effects against antipsychotic-induced
weight gain. Moreover, a strong relationship between presence of
the intragenic HTR2C rs1414334 C allele and the metabolic syn-
drome in adult patients using antipsychotic medication has been
described by authors from our group (Mulder et al. 2007). Not all
studies, however, have detected significant associations between
HTR2C T/C polymorphisms and clozapine-induced weight gain
(Park et al. 2008).
The association between risperidone-induced weight gain and
HTR2C gene polymorphisms has not yet been examined in children
and adolescents. We address this in the present study, in which we
look at weight changes after 8 weeks of treatment with risperidone,
in a flexible-dose, open label, prospective design. In addition to
reporting absolute weight changes, we also use height and weight
measures against appropriate age and gender normative values to
calculate BMI-standardized z scores (Martin et al. 2000). This
approach has the advantage of taking age and gender pediatric
growth patterns into account.
Methods
Subjects
The sample consisted of 32 children (28 boys and 4 girls; mean
age¼ 8.74, standard deviation [SD]¼ 2.83, range¼ 5–16 years)
with a pervasive developmental disorder (based on clinical diag-
nosis with corroboration from the Autism Diagnostic Interview—
Revised; Lord et al. 1994) who had participated in an open 6-month
trial of risperidone followed by a placebo-controlled withdrawal
(Troost et al. 2005). In addition to a diagnosis of pervasive devel-
opmental disorder, subjects also had serious behavioral problems
such as tantrums, aggression, and/or self-injurious behavior. All
participants were referred patients of either the Groningen or
Utrecht University Child and Adolescent Psychiatry Center. The
present study examined the effects of risperidone on weight and
BMI in relation to HTR2C polymorphisms during the first 8 weeks
of treatment. Of the 36 children who entered the trial, 32 subjects
had a DNA sample taken for genotyping. Four of the 32 patients
participated for < 8 weeks: one male patient discontinued after 5
weeks because of dystonia, another male patient after 7 weeks
because of increased anxiety, and two girls stopped after 6 weeks
for unknown reasons. We did not examine weight gains after 6
months of risperidone treatment, because only 22 of the 32 patients
with available DNA completed the 6-month trial (i.e., only ris-
peridone responders, as assessed after 8 weeks of treatment; Troost
et al. 2005).
Prior to the study, ineffective medications were gradually
withdrawn in a 7- to 28-day washout period. In the case of co-
occurring attention-deficit/hyperactivity disorder, stimulants were
allowed to be continued, provided no changes during the study
would occur; 8 of the 32 patients used stimulants, in all cases
methylphenidate.
At study entry, children <45 kg of weight were given risper-
idone at an initial dose of 0.5mg at bedtime, which was increased to
0.5mg twice daily at day 7. The dose was gradually increased in
0.5mg increments to a maximum of 2.5mg/day by day 29. Chil-
dren who weighed >45 kg could be prescribed slightly higher
doses, with maximum daily doses of 3.5mg by day 29. Dosing was
flexible: clinicians were free to delay a scheduled increase or to
reduce the medication dose depending on response or adverse
events. At study end, mean daily dose of risperidone was 1.70mg
(SD¼ 0.78mg, range¼ 0.50–3.50mg).
The aim and study procedures were fully explained to the sub-
jects and both parents before the parents’ written consent was
obtained, which included consent for genetic testing and permis-
sion to publish. If the subjects were 12 years or older, the written
informed consent of the parents was obtained along with the
patients’ assent. The study was approved by the Dutch Central
Review Board (The Hague, The Netherlands).
Genotyping
DNA was extracted from 80mL of ethylenediaminetetraacetic
acid–anticoagulated whole blood with a Generation Capture Col-
umn Kit (Gentra Systems, Minneapolis, MN) according to the
manufacturer’s instructions. We determined genotypes of
rs3813929: C>T (-759C/T), in the promoter region of the X-
linked HTR2C gene, and of rs1414334: C>G, an intragenic
polymorphism in intron 5 close to the HTR2C 3’ untranslated re-
gion. Genotyping was performed by pyrosequencing as described
previously (Mulder et al. 2007). The genotyping results were
blinded to the researcher and were not available to the treating
psychiatrist before data analysis.
Data analysis
Possible differences in baseline BMI-standardized z scores,
based on Dutch age- and gender-normed growth charts (available at
http://groeiweb.pgdata.nl), between carriers and noncarriers of the
rs3813929 T allele and the rs1414334 C allele, respectively, were
evaluated with t-tests. Further, we performed repeated measures
analysis of variance (ANOVA). In the first analysis, we only looked
at pre- and posttreatment BMI-standardized z scores, but also report
changes in body weight. This was followed by entering the pres-
ence of the rs3813929 T allele and the rs1414334 C allele, re-
spectively, as between-subject factor, to assess crude effects of
genotypes. Finally, we also added risperidone dose, age, gender,
and concomitant use of methylphenidate as covariates. To rule out
possible effects of baseline weight, we additionally did a repeated
measures ANOVA on body weight between carriers and noncar-
riers of the rs3813929 T allele, with baseline weight as covariate. In
subjects participating for <8 weeks, we used the last observation
carried forward model. All tests were two-tailed and used p-values
<0.05 to indicate statistical significance.
Results
Age- and gender-normed BMI-standardized z scores changed
significantly (univariate repeated measures ANOVA: F¼ 50.9,
degrees of freedom [df ]¼ 31, p< 0.001) from baseline (mean
standardized BMI¼ 0.53 z, SD¼ 1.27 z, range¼2.20–3.30 z) to
posttreatment (mean standardized BMI¼ 1.03 z, SD¼ 1.26 z,
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range¼1.40–3.50 z), corresponding to a mean weight gain of
2.9 kg. Standardized BMI scores increased in 28 children
(range¼ 0.10–1.60 z), remained unchanged in 3 children, and de-
creased in 1 child (by 0.3 z). In absolute kg, all except one child
(who experienced a weight loss of 0.3 kg) gained weight
(range¼ 0.6–7.7 kg).
Seven of the 32 children (21.9%; 4 males and 3 females) carried
the rs3813929 T allele; the rs1414334 C allele was present in 5 of
the 32 children (15.6%; all males). There were no statistically
significant differences in baseline BMI-standardized z scores or in
absolute weight (t-test: t¼0.60, df¼ 30, p¼ 0.66; and t¼1.67,
df¼ 30, p¼ 0.11, respectively) between carriers of the rs3813929
T allele (mean¼ 0.79 z, SD¼ 1.37 z, range¼0.60–3.30 z; and
mean¼ 45.4 kg, SD¼ 29.4 kg, range¼ 22.8–107.2 kg, respectively)
and those who did not carry the allele (mean¼ 0.46 z, SD¼ 1.27 z,
range¼2.20–3.00 z; and mean¼ 33.2 kg, SD¼ 12.1 kg, range¼
20.2–61.5 kg, respectively). Similarly, no such differences were
present between carriers and noncarriers of the rs1414334 C allele.
Entering the presence of the rs3813929 T allele as between-subject
factor in the repeatedmeasures ANOVA revealed a significant effect
of this allele on risperidone-induced increases in BMI-standardized
z scores (F¼ 18.7, df¼ 30, p< 0.001). Carriers of the rs3813929
T allele gained an average of 0.043 BMI-standardized z scores
(SD¼ 0.17 z, range¼0.30–0.20; from a group mean of 0.79 to
0.83) versus 0.64 z (SD¼ 0.35 z, range¼ 0.00–1.60 z; from 0.46 to
1.09 z) for noncarriers (Fig. 1). The weight gain in the group with the
rs3813929 T allele was 1.84 (SD¼ 1.51 kg) compared with 3.23
(SD¼ 1.47 kg) for the noncarriers. In contrast, presence of the
rs1414334 C allele played no significant role (F¼ 2.08, df¼ 30,
p¼ 0.16). This reflects effect sizes (Cohen’s d) of the rs3813929 T
allele on increase in BMI-standardized z scores and weight gain of
2.16 and 0.93, respectively.
Table 1 shows the results of a repeated measures ANOVA
regarding the number of possible determinants of risperidone-
induced gain in BMI-standardized z scores. Gender (n of girls¼ 4)
and the concomitant use of methylphenidate (n¼ 8) were not
associated with risperidone-induced weight gain. Gain in BMI-
standardized z scores appeared to be associated with younger age
and higher doses of risperidone: children below the median age of
8.26 years gained an average of 0.63 BMI-standardized z scores
versus 0.38 z for children above 8.26 years (mean weight gain was
3.0 and 2.9 kg, respectively). Children receiving less than the me-
dian level risperidone (i.e., 1.5mg/day) gained an average of 0.38 z
BMI versus 0.57 z for children receiving 1.5mg/day or more
(average weight gain was 2.6 and 3.1 kg, respectively). Mean ris-
peridone doses in mg/kg/day were similar in children below
(0.053mg/kg/day) and above (0.047mg/kg/day) the median age.
Finally, a repeated measures ANOVA on body weight between
carriers and noncarriers of the rs3813929 T allele, with baseline
weight as covariate, confirmed the significant effect of the T allele
(F¼ 8.61, df¼ 30, p¼ 0.006).
Discussion
The main finding of our study is that children and adolescents
with the variant 759T allele in the promoter of the HTR2C gene
are protected against risperidone-induced weight gain. In children
without this variant, 8 weeks of flexible-dose use of risperidone
was associated with an age- and gender-normed mean increase of
0.64 BMI-standardized z scores (absolute mean weight gain of
3.23 kg) versus little or no (i.e., 0.043 standardized z scores; mean
weight gain of 1.81 kg) increase in carriers of the 759T allele.
Although findings with clozapine have been somewhat inconsis-
tent (Basile et al. 2002; Reynolds et al. 2002; Tsai et al. 2002;
Theisen et al. 2004), these results are in line with the protective
effect of the variant T allele against antipsychotic-induced weight
gain in several studies of adults with schizophrenia (Ellingrod
et al. 2005; Templeman et al. 2005; Lane et al. 2006; Ryu et al.
2007).
Risperidone acts as an antagonist against HTR2C (Canton et al.
1994). There is ample evidence that the HTR2C is directly involved
in weight regulation, probably through appetite control (Somerville
et al. 2007). The 759T HTR2C promoter allele shows higher
transcription levels of the HTR2C gene than the 759C allele
(Buckland et al. 2005) and has been found to be more common in
obese than in nonobese women (Pooley et al. 2004). Interestingly,
5HTR2C knockout mice are prone to increased feeding and obesity
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FIG. 1. Change in age- and gender-normed body mass index–
standardized z scores after a 6-week open-label treatment with ris-
peridone in seven carriers of the HTR2C promoter T allele (gaining
an average of 0.043þ 0.017 body mass index–standardized z scores)
and 25 non–T-allele carriers (mean weight gain of 0.64þ 0.35 z).
HTR2C¼ 5-hydroxytryptamine 2C receptor gene.
Table 1. Results of Repeated Measures Analysis
of Variance Regarding Change in Body Mass
Index–Standardized z Scores in 32 Children
with a Pervasive Developmental Disorder Receiving
8 Weeks of Treatment with Risperidone
Possible determinants
of weight gaina
Repeated measures
statistics
Presence of rs3813929 T allele F¼ 8.18, df¼ 26, p¼ 0.008
Gender F¼ 1.08, df¼ 26, p¼ 0.31
Use of methylphenidate F¼ 0.030, df¼ 26, p¼ 0.86
Age F¼ 6.21, df¼ 26, p¼ 0.019
Risperidone dose F¼ 4.39, df¼ 26, p¼ 0.046
aBetween subject factors or covariates.
Abbreviation: df¼ degrees of freedom.
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(Tecott et al. 1995; Memon et al. 2000). Moreover, agonists of the
HTR2C have been shown to decrease weight and food intake in rats
(Luo and Li 1991; Rosenzweig-Lipson et al. 2006), mice (Somer-
ville et al. 2007), and humans (Sargent et al. 1997; Nilsson 2006).
Further, in animal studies, it has been demonstrated that antipsy-
chotics downregulate HTR2C mRNA (Buckland et al. 1997). It is
conceivable that high baseline expression levels of HTR2C, as in
759T carriers, may tend to mitigate antagonistic and down-
regulatory effects of risperidone at the receptor.
Apart from the influence of the 759C/T polymorphism, higher
risperidone dose and younger age appeared to be positively asso-
ciated with weight gain in our study. Although Martin et al. (2004)
did not observe an association between risperidone dose and weight
gain in the Research Units on Pediatric Psychopharmacology
(RUPP) Autism Network study, a clear dosing effect has been
identified in adult studies (Lane et al. 2003; Theisen et al. 2004). It
should be noted that risperidone doses in the present study, pre-
scribed for behavior problems, have been lower than those typically
used in the treatment of psychoses. A pooled data analysis based on
available double-blind and open trials, as well as case series, also
had shown that risperidone-induced weight gain is most pro-
nounced in the preadolescent years and decreases with advancing
age (Safer 2004). In the RUPP study, however, younger age was not
associated with weight gain (Martin et al. 2004). Martin et al.
(2004) did note that weight gain was most rapid in the first 2 months
of treatment. Thus, the fact that the RUPP study investigated weight
change after 6 months of risperidone treatment and our study
looked at effects after 2 months of treatment may be an important
difference. Moreover, our study included eight children (25% of
study participants) on methylphenidate, whereas the RUPP study
did not allow treatment with another medication.
Our study has clear clinical implications. It provides additional
confirmation that weight gain is a frequent and important adverse
effect of risperidone in children. Younger children and those using
higher doses may be at increased risk of weight gain. However, the
results also indicate that this adverse effect is unlikely to occur in a
substantial proportion of children (those with the 759T allele).
Given the physiological and psychosocial consequences of atypical
antipsychotic-induced weight gain, genotyping the HTR2C pro-
moter 759C/T polymorphism may become a standard clinical
practice when considering treating children with such agents.
In conclusion, the small sample size is acknowledged as an
important limitation of the present study that underlines the pre-
liminary character of our study findings, specifically given the
combination of the low number of patients and the uneven distri-
bution of genotypes. Moreover, all patients had an autism spectrum
disorder and the far majority of patients were boys, limiting the
generalizability of our findings. Therefore, it is clear that replica-
tion is required. However, the use of BMI-standardized z scores,
rather than absolute weight, made the groups similar in terms of
variance, and thus the results of statistical testing more sensitive.
Still, the limited study power may be one explanation for the lack of
effect of the rs1414334 C allele. This and other candidate poly-
morphisms possibly associated with risperidone-induced weight
gain (such as adrenergic alpha2a receptor genes, the gene for leptin
guanine nucleotide binding protein, and the gene for synaptomal-
associated protein [25 kDa]; Muller and Kennedy 2006) should be
examined along with the 759C/T polymorphism in future studies
(with larger samples sizes) of antipsychotic-induced weight gain in
children. Future studies could also investigate the effectiveness of
weight gain prevention programs in children treated with antipsy-
chotic medications.
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